Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world

If you are trying to figure out whether to hold onto your Kenvue shares, add more to your portfolio, or sit this one out, you are definitely not alone. Investors have watched Kenvue’s stock price take a hit lately,

Kenvue (NYSE: KVUE) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ratings,

Kenvue Inc. (NYSE:KVUE) has been in the news lately after President Trump asserted that taking Tylenol can increase autism in unborn children. The firm’s shares have lost 22% over the month.

Kenvue's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Learn more about KVUE stock here.

Shares of Kenvue Inc. slid 4.09% to $16.17 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.50% to 6,604.72 and Dow Jones Industrial Average falling 0.

Kenvue shares rose 6% in premarket trading on Tuesday, set to rebound from a record low hit in the previous session as U.S. President Donald Trump linked its popular pain medication Tylenol to autism.

Shares of consumer healthcare firm Kevnue dropped to a record low during regular trading Monday, then made up some ground afterhours as President Trump warned that acetaminophen, the active ingredient in Kenvue's Tylenol,